Lupin's subsidiary has signed a pact with Celnova Pharma to distribute NaMuscla in Argentina and Colombia. The drug treats non-dystrophic myotonic disorders, improving quality of life for patients. Celnova will handle registration, importation, storage, and sales, while Lupin will manufacture and supply the product.
